Latest Breaking News On - Howardl weiner - Page 7 : comparemela.com

Regulus Therapeutics Reports Second Quarter 2023 Financial Results and Recent Updates

Tiziana (NASDAQ: TLSA) Continues The Fight Against Multiple Sclerosis, Will Announce 6-Month Results For Its Novel Treatment Soon - Tiziana Life Sciences (NASDAQ:TLSA), Sanofi (NASDAQ:SNY)

Tiziana Life Sciences (NASDAQ: TLSA), a clinical-stage biotechnology company focused on developing immunotherapies, will soon announce the 6-month results for patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS) receiving its novel intranasal treatment, foralumab. 

Phase 1 Results Are "Extraordinary," Says Chairman Of Scientific Advisory Board As Biomedical Company Preps Phase 2 Trial For MS Treatment - Bayer (OTC:BAYRY), Sanofi (NASDAQ:SNY)

Tiziana Life Sciences (NASDAQ: TSLA) has presented data from its clinical trial showing that five of its six patients with an advanced stage of multiple sclerosis (MS) have shown a reduction in microglia activity,

Regulus Therapeutics Announces Update on Preclinical Studies in Amyotrophic Lateral Sclerosis in Collaboration with Researchers from Harvard's Brigham and Women's Hospital

Program advances to lead compound evaluation in preclinical in vivo models Preliminary data for in vivo studies are expected in second half of 2023 SAN DIEGO, June 20, 2023 /PRNewswire/ Regulus. | June 20, 2023

Tiziana Life Sciences (NASDAQ: TLSA) Announces Positive Data In Its Secondary-Progressive Multiple Sclerosis Trial, What Could This Mean For The Company? - Tiziana Life Sciences (NASDAQ:TLSA), Sanofi (NASDAQ:SNY)

Company Moves Ahead With Drug Development